This study is evaluating possible non-intraocular pressure (IOP) related effects of the
alpha-1 agonist brimonidine in human subjects affected by a progressive glaucomatous optic
neuropathy. Brimonidine was proven as neuroprotective in several pre-clinical animal studies.